Women's perspectives on counseling about risks for medication-induced birth defects
- PMID: 19637252
- PMCID: PMC2806515
- DOI: 10.1002/bdra.20618
Women's perspectives on counseling about risks for medication-induced birth defects
Abstract
Purpose: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs).
Methods: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus.
Results: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP.
Conclusions: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.
Copyright 2009 Wiley-Liss, Inc.
Conflict of interest statement
Conflict of Interest None disclosed.
Similar articles
-
Perspectives of primary care clinicians on teratogenic risk counseling.Birth Defects Res A Clin Mol Teratol. 2009 Oct;85(10):858-63. doi: 10.1002/bdra.20599. Birth Defects Res A Clin Mol Teratol. 2009. PMID: 19591115 Free PMC article.
-
Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study.Birth. 2018 Mar;45(1):50-54. doi: 10.1111/birt.12318. Epub 2017 Oct 20. Birth. 2018. PMID: 29052257
-
Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.J Gen Intern Med. 2012 Jul;27(7):831-8. doi: 10.1007/s11606-012-1991-y. J Gen Intern Med. 2012. PMID: 22297687 Free PMC article. Clinical Trial.
-
Human teratogens update 2011: can we ensure safety during pregnancy?Birth Defects Res A Clin Mol Teratol. 2012 Mar;94(3):123-8. doi: 10.1002/bdra.22887. Epub 2012 Feb 13. Birth Defects Res A Clin Mol Teratol. 2012. PMID: 22328359 Free PMC article. Review.
-
Preconception Care: Improving the Health of Women and Families.J Midwifery Womens Health. 2016 May;61(3):356-64. doi: 10.1111/jmwh.12465. J Midwifery Womens Health. 2016. PMID: 27218593 Review.
Cited by
-
Special Considerations for Women of Reproductive Age on Anticoagulation.J Gen Intern Med. 2022 Aug;37(11):2803-2810. doi: 10.1007/s11606-022-07528-y. Epub 2022 May 31. J Gen Intern Med. 2022. PMID: 35641728 Free PMC article. Review.
-
"I know my body better than you:" patient focus groups to inform a decision aid on oral corticosteroid use during pregnancy.Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):451-461. doi: 10.1002/pds.5183. Epub 2020 Dec 22. Pharmacoepidemiol Drug Saf. 2021. PMID: 33314542 Free PMC article.
-
A Qualitative Study of Pregnant Women's Perspectives on Antibiotic Use for Mom and Child: Implications for Developing Tailored Health Education Interventions.Antibiotics (Basel). 2020 Oct 15;9(10):704. doi: 10.3390/antibiotics9100704. Antibiotics (Basel). 2020. PMID: 33076539 Free PMC article.
-
Perceptions of the Value of Clinical Pharmacy Medication Review for Women During Early Pregnancy.J Manag Care Spec Pharm. 2020 Oct;26(10):1301-1308. doi: 10.18553/jmcp.2020.26.10.1301. J Manag Care Spec Pharm. 2020. PMID: 32996386 Free PMC article.
-
True Choice in Reproductive Care: Using Cultural Humility and Explanatory Models to Support Reproductive Justice in Primary Care.J Gen Intern Med. 2021 May;36(5):1395-1399. doi: 10.1007/s11606-020-06245-8. Epub 2020 Sep 24. J Gen Intern Med. 2021. PMID: 32974726 Free PMC article.
References
-
- Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407. - PubMed
-
- Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8(4):214–220. - PubMed
-
- Centers for Birth Defects Research and Prevention. 2004. [cited 2004 July 15, 2004]; Available from: http://www.cdc.gov/ncbddd/pub/cbdrpbk.pdf.
-
- Elsinga J, de Jong-Potjer LC, van der Pal-de Bruin KM, le Cessie S, Assendelft WJ, Buitendijk SE. The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy. Womens Health Issues. 2008;18(6 Suppl):S117–125. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
